Oncology
Primary Brain Tumor
1
Pipeline Programs↗
1
Active Trials↗
2
Companies Involved↗
Primary Brain Tumor is an early-stage landscape with 1 program across 2 companies. The most active players are Roche, Bristol-Myers Squibb.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 21
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
12
clinical trials
Completed11 · 92%
Recruiting1 · 8%
Clinical Trials
Trial Activity
12 trials
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Completed·—·Phase 1·NCT00003484·21 enrolled
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy
Completed·—·Phase 2·NCT00463203·54 enrolled
Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT00639262·35 enrolled
Gene Therapy in Treating Patients With Primary Brain Tumors
Completed·—·Phase 1·NCT00002824
Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors
Completed·—·Phase 1·NCT00547131·12 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)